A brain implant to treat depression gets FDA greenlight to start trials
AI-summarised brief · reviewed before publication
The US Food and Drug Administration (FDA) has approved a human trial for a brain implant, known as DOT, developed by Motif Neurotech to treat treatment-resistant depression. The blueberry-sized implant, which is wirelessly powered, aims to deliver electrical stimulation to activate parts of the brain's central executive network that are inactive in people with major depressive disorder. The implant is designed to be implanted in a 20-minute outpatient procedure.
💡 Why It Matters
- · The success of this brain implant could revolutionize the treatment of depression, offering a new option for the millions of adults in the US living with treatment-resistant depression.
- · By providing a non-invasive, outpatient solution, Motif's technology could potentially make a significant impact on mental health care, offering hope to those who have not responded to traditional therapies.